Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2015-05-06 16:06:49
Reporting Period:
Filing Date:
Accepted Time:
2015-05-06 16:06:49
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1501756 Avalanche Biotechnologies Inc. AAVL Biological Products, (No Disgnostic Substances) (2836) 205258327
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1614876 Hans Hull C/o Avalanche Biotechnologies, Inc.
1035 O'brien Drive, Suite A
Menlo Park CA 94025
Svp, Business Operations No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-05-04 5,000 $0.19 16,320 No 4 M Direct
Common Stock Disposition 2015-05-04 5,000 $30.87 11,320 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2015-05-04 5,000 $0.00 5,000 $0.19
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
22,500 2022-02-23 No 4 M Direct
  1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
  2. This transaction was executed in multiple trades in prices ranging from $29.9000 to $32.0200, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  3. The shares subject to the option vest and become exercisable in 48 successive, equal monthly installments on each monthly anniversary of February 1, 2012, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.